WORTHING, UNITED KINGDOM -- (Marketwired) -- 05/09/16 -- Allergy Therapeutics (AIM: AGY)
9 May 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Allergy Therapeutics announces positive top-line results from the PQBirch204 Phase II study for birch-induced seasonal allergic rhinitis
Allergy Therapeutics, (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces positive top-line results from the Company's PQBirch204 Phase II study, a multi-centre, double-blind, placebo-controlled study designed to explore the safety and response of different cumulative doses of Birch Modified Allergen Tyrosine adsorbed and MPL® (POLLINEX® Quattro Birch) for birch pollen induced seasonal allergic rhinitis.
The study randomised 371 patients into six cumulative dosing regimens plus a placebo, evaluating the change in Total Symptom Score (TSS) following a conjunctival provocation test (CPT) with the objective to achieve a dose recommended for Phase III development.
Results summary of the PQBirch 204 Phase II study programme
Click on, or paste the following link into your web browser, to view the associated PDF document.
This information is provided by RNS
The company news service from the London Stock Exchange
For further information, please contact:
+44 (0) 1903 845 820
Chief Executive Officer
+44 (0) 20 7886 2500
Freddy Crossley / Peter Steel / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura Thornton